Review of Interleukin-6 and Cardiopulmonary Bypass-Related End-Organ Injury Along With the Potential for Mitigation With Tocilizumab

Althena Yu, Junedh M. Amrute, Pirooz Eghtesady

Research output: Contribution to journalReview articlepeer-review

Abstract

Cardiopulmonary bypass (CPB) is essential for the conduct of open-heart procedures. While lifesaving, CPB can be associated with significant end-organ injuries believed to result from inflammatory responses triggered by the extracorporeal surfaces encountering cellular elements in the blood stream. In this review, we discuss the role of interleukin-6 (IL-6) and the potential for Tocilizumab, an anti-IL-6 receptor antibody, in mitigating these effects. We compare the inflammatory responses in CPB and cytokine storm, a clinical condition in which Tocilizumab has been effectively implemented. Finally, we examine why corticosteroids, used to reduce the morbidity of CPB, may not effectively reduce IL-6 levels.

Original languageEnglish
JournalWorld Journal for Pediatric and Congenital Heart Surgery
DOIs
StateAccepted/In press - 2024

Keywords

  • cardiopulmonary bypass (CPB)
  • congenital heart disease
  • inflammation
  • interleukin 6 (IL-6)
  • pediatric heart surgery
  • Tocilizumab

Fingerprint

Dive into the research topics of 'Review of Interleukin-6 and Cardiopulmonary Bypass-Related End-Organ Injury Along With the Potential for Mitigation With Tocilizumab'. Together they form a unique fingerprint.

Cite this